摘要再灌注治疗是急性缺血性卒中（acute ischemic stroke, AIS）的主要治疗手段，但其应用受到严格时间窗和适应证限制。近年来，再灌注治疗决策正从传统的时间窗向组织窗转变，新型溶栓药的疗效不逊于阿替普酶且使用更为便捷。针对特定类型患者的再灌注治疗获益证据也在不断积累。文章系统综述了AIS的再灌注治疗研究进展，以期为优化临床实践提供参考。

abstractsReperfusion therapy is the main treatment approach for acute ischemic stroke (AIS), but its application is limited by strict time windows and indications. In recent years, the decision-making for reperfusion therapy has been shifting from the traditional time window to the tissue window, and novel thrombolytic agents exhibit efficacy comparable to alteplase with more convenient administration. Evidence supporting the benefits of reperfusion therapy in specific patient populations is also accumulating continuously. This article systematically reviews the research progress of reperfusion therapy for AIS, in order to provide reference for optimizing clinical practice.